EKF vs. CREO, IUG, NCYT, IHC, POLX, AVO, RUA, SUN, MHC, and BELL
Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Inspiration Healthcare Group (IHC), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), MyHealthChecked (MHC), and Belluscura (BELL). These companies are all part of the "medical devices" industry.
EKF Diagnostics vs. Its Competitors
EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.
In the previous week, Creo Medical Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 1.11 beat Creo Medical Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.
EKF Diagnostics has a net margin of 9.37% compared to Creo Medical Group's net margin of -73.93%. EKF Diagnostics' return on equity of 7.03% beat Creo Medical Group's return on equity.
EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 56.1% of Creo Medical Group shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 22.4% of Creo Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
EKF Diagnostics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Summary
EKF Diagnostics beats Creo Medical Group on 10 of the 13 factors compared between the two stocks.
Get EKF Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EKF Diagnostics Competitors List
Related Companies and Tools
This page (LON:EKF) was last updated on 8/17/2025 by MarketBeat.com Staff
MarketBeat All Access